SPRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's long-term focus, beginner status, and available capital, ARS Pharmaceuticals (SPRY) is not a strong buy at this moment. Despite positive catalysts such as product approval and hedge fund interest, the company's poor financial performance, lack of immediate trading signals, and bearish technical indicators suggest waiting for further clarity before investing.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downward trend. Key support is at 7.829, and resistance is at 8.471. The stock is trading near its pivot point of 8.15.
Approval of neffy by Health Canada, with a planned launch in summer
Licensing agreement with ALK-Abelló A/S, generating $155 million in upfront and milestone payments, with potential for an additional $310 million.
Hedge funds are significantly increasing their positions, with a 326% increase in buying activity over the last quarter.
Poor financial performance in Q4 2025, with revenue down 67.56% YoY, net income down 182.76% YoY, and EPS down 200%.
Bearish technical indicators and lack of immediate trading signals.
No recent congress trading data or significant insider activity.
In Q4 2025, ARS Pharmaceuticals saw a significant decline in financial performance. Revenue dropped 67.56% YoY to $28.09 million, net income fell 182.76% YoY to -$41.32 million, and EPS declined 200% YoY to -0.42. Gross margin also fell 21.12% YoY to 78.09.
Northland initiated coverage with an Outperform rating and a $25 price target, citing the disruptive potential of neffy, a needle-free intranasal epinephrine product. Analysts expect adoption to be driven by new prescriptions and conversion from injectable users.
